Augment: Relapsed/Refractory Indolent NHL Patients Were More Sensitive to Next Treatment Following Lenalidomide/Rituximab (R2 ) Than Rituximab/Placebo
Hematological Oncology - United Kingdom
doi 10.1002/hon.42_2630
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Wiley